dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Macia, Manuel |
dc.contributor.author | DÍAZ ENCARNACIÓN, MONTSERRAT MERCEDES |
dc.contributor.author | Pomares Mallol, Elisenda |
dc.contributor.author | García Castells, Alejandra |
dc.contributor.author | Escribano, Cristina |
dc.contributor.author | Solans-Laque, Roser |
dc.date.accessioned | 2024-02-01T13:24:24Z |
dc.date.available | 2024-02-01T13:24:24Z |
dc.date.issued | 2024 |
dc.identifier.citation | Macía M, Díaz-Encarnación M, Solans-Laqué R, Pomares Mallol E, García Castells A, Escribano C, et al. A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain. Expert Rev Pharmacoecon Outcomes Res. 2024;24(2):227–35. |
dc.identifier.issn | 1473-7167 |
dc.identifier.uri | https://hdl.handle.net/11351/10956 |
dc.description | Avacopan; Anàlisi cost-utilitat; Vasculitis |
dc.description.sponsorship | This cost-utility study has been funded by Vifor Fresenius Medical Care Renal Pharma. |
dc.language.iso | eng |
dc.publisher | Taylor & Francis |
dc.relation.ispartofseries | Expert Review of Pharmacoeconomics & Outcomes Research;24(2) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Vasculitis - Tractament |
dc.subject | Cost-eficàcia |
dc.subject | Autoanticossos |
dc.subject.mesh | Vasculitis |
dc.subject.mesh | Antibodies, Antineutrophil Cytoplasmic |
dc.subject.mesh | Cost-Benefit Analysis |
dc.title | A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1080/14737167.2023.2297790 |
dc.subject.decs | vasculitis |
dc.subject.decs | anticuerpos anticitoplasma de neutrófilos |
dc.subject.decs | análisis coste-beneficio |
dc.relation.publishversion | https://doi.org/10.1080/14737167.2023.2297790 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Macía M] Nephrology Service, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain. [Díaz-Encarnación M] Nephrology Service, Fundació Puigvert, Barcelona, Spain. [Solans-Laqué R] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pomares Mallol E, García Castells A] Market Access, PharmaLex, Barcelona, Spain. [Escribano C] Medical Department, CSL Vifor, Barcelona, Spain |
dc.identifier.pmid | 38126738 |
dc.identifier.wos | 001130140200001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |